Neurocrine Bio. (NBIX) PT Raised to $149 at RBC Capital

September 5, 2025 5:23 AM EDT Send to a Friend
RBC Capital analyst Brian Abrahams raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $149.00 (from $144.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login